Force recommended research criteria for the estimation of prodromal PD. Obj ecti ves: We aimed to evaluate, for the first time, the criteria in first-degree relatives of Ashkenazi Jewish G2019S-LRRK2 PD patients, who are considered a population at risk for developing PD, and assess the sensitivity and specificity of the criteria in identifying phenoconverters. Met ho ds: Participants were evaluated longitudinally over a period of 5 years (average follow-up: 49.2 6 12.3 months). Likelihood ratios and probability estimations were calculated based on the International Parkinson and Movement Disorder Society Research Criteria for Prodromal Parkinson's Disease markers and examined for each assessment point. Resu lts: One hundred twenty healthy carriers (49.53 6 13.4 years; 54% female) and 111 healthy noncarriers (48.43 6 15.79 years; 49% female) participated in this study. Probability scores were significantly higher in healthy carriers than healthy noncarriers (P < 0.0001). Of the 20 participants (8.6%) who met criteria for probable prodromal PD at baseline, 17 were healthy carriers. Participants who reached the threshold were older (P < 0.0001), had higher UPDRS-III (P < 0.001), lower cognitive function (P 5 0.001), and more nonmotor symptoms (P < 0.0001), compared to those who did not. Ten participants were diagnosed with incident PD within 5 years from baseline resulting in a specificity of 91.82% (95% confidence interval: 86.69-96.94), sensitivity of 80% (95% confidence interval: 55.21-100), positive predictive value of 47.06% (95% confidence interval: 23.33-70.79), and negative predictive value of 98.06% (95% confidence interval: 95.39-100). All 10 phenoconvertors were G2019S-LRRK2 carriers. C on clusi o ns: The results showed the utility of using the criteria and high sensitivity and specificity in identifying prodromal PD in this high-risk unique cohort. These results may be valuable for future disease modification clinical trials.
The pathological changes of Parkinson's disease (PD) can start decades before the appearance of cardinal motor symptoms. Detecting patients at the premotor stage will be crucial for future clinical trials aiming at modifying progression at the earliest stages of the disease. In 2015, the International Parkinson and Movement Disorder Society (MDS) Task Force recommended research criteria using probability estimation for the diagnosis of prodromal PD. 1 The criteria include risk factors as well as motor and nonmotor prodromal markers. These prodromal criteria need to be validated in cohorts at increased risk of developing PD.
The MDS Research Criteria for Prodromal PD has been examined in four different high risk cohorts: individuals with diagnosed rapid eye movement (REM) sleep behavior disorder (RBD) 2 ; Early Detection of Neurodegeneration cohort (TREND study 3 : the presence of probable RBD, depression, and/or hyposmia); the population-based Prospective Evaluation of Risk Factors for Idiopathic Parkinson's Syndrome (PRIPS) 3 ; and a general elderly population (Bruneck study). 4 Based on their available data, these studies reported a wide range of sensitivity (14-81.3%) and positive predictive value (PPV; 19-81%) for the prediction of PD but relatively high specificity (67.9-99.2%).
The autosomal-dominant G2019S mutation in exon 41 (leucine rich repeat kinase 2; LRRK2) is increased in Ashkenazi Jewish (AJ) PD patients, 5 where rates approach as high as 26% in familial and 14% in apparently sporadic PD. 5, 6 The asymptomatic firstdegree relatives of AJ PD patients with the G2019S-LRRK2 mutation, represent a population at risk for developing PD. Yet, penetrance is incomplete and age dependent, estimated at 80 years of age as 26% (95% confidence interval [CI] : 0.18-0.36) among AJ 7 and 42.5% (95% CI: 26.3-65.8) in G2019S-LRRK2 carriers who are non-AJ. 8 The value of the MDS Research Criteria in such a unique population is of special importance for disease prevention and modification trials. The estimated low penetrance further highlights the need to identify mutation carriers at risk for development of PD for future trials.
Thus, the aims of this study were to: (1) evaluate the likelihood ratio (LR) and PD probability in unaffected AJ, carriers, and noncarriers of the G2019S-LRRK2 mutation; (2) explore the change in LR's and probability over time in this cohort; and (3) assess the sensitivity and specificity of the MDS prodromal criteria in identifying phenoconverters (incident PD) in this unique cohort.
PATIENTS AND METHODS

Participants
The study was conducted by the LRRK2 AJ Consortium, which includes centers in Israel (Tel Aviv Medical Center; TLVMC) and New York (Beth Israel Medical Center; BI and Columbia University Medical Center; CU). A total of 231 healthy AJ relatives of PD patients, who were carriers of the G2019S LRRK2 mutation, participated in this double-blind (to mutation status) observational longitudinal study (BI 5 30, CU 5 46, and TLVMC 5 155; Table 1 ). Participants were excluded if they were diagnosed with PD or dementia or any symptoms suggesting possible parkinsonism (UPDRS-III > 7) at baseline, or if they carried one of the seven common mutations among AJ in the glucocerebrosidase 1 gene (GBA1). The study was approved by the institutional review boards at all sites. All participants provided informed consent. Participants were followed every 18 to 24 months, (average duration: 49.2 months; range, 17-64). During Mean and SD are provided as well as range and percent.
each follow-up visit, all participants were assessed again for parkinsonism by a movement disorders specialist blinded to genetic status to assess phenoconversion (based on the UK Brain Bank criteria 9 ).
Outcomes
In order to calculate the post-test probability for conversion to PD for each participant, individualized LR scores were calculated, at baseline and during each follow-up visit, for each MDS prodromal criterion according to the recommended scores. 1 Except SN hyperechogenicity and single-photon emission computed tomography (SPECT)/PET, all items of the MDS prodromal criteria were evaluated in our cohort. Risk markers included: age, sex, family history, G2019S-LRRK2 genetic status, habits, and occupational exposure. Prodromal markers included subtle motor and nonmotor symptoms with the specified cutoffs: Motor function was tested using the UPDRS-Part III 9 with a cut-off score of >3 (excluding action tremor). For olfactory function, a score <20th percentile for the individual's age group and sex on the University of Pennsylvania Smell Identification Test (UPSIT) 10 was considered high risk. RBD was assessed using the REM Sleep Behavior Disorder Questionnaire (RBDQ) 11 with a score of 6 reflecting RBD based on the exploration of PD-related dysfunction. 18 Urinary, erectile, and bowel symptoms received a high-risk LR if scored 1 on the specified item on the Non-Motor Symptom Questionnaire (NMSQ) 12 or 2 on the corresponding item on the Scale for Autonomic Function (SCOPA-AUT) 13 ; orthostatic hypotension was tested by manual measurement of blood pressure in supine position and after 1 minute of standing. A drop in systolic blood pressure >20 or >10 mm Hg with positive symptoms was considered high risk. A socre of 14 on the Beck Depression Inventory-II 14 or 6 on the Geriatric Depressions Scale-15 15 were used as the cutoff for depression whereas a score of >10 on the Epworth Sleepiness Scale (ESS) 16 reflected somnolence. Smoking, caffeine consumption, and pesticide and occupational exposure were evaluated using the PD Risk Factor Questionnaire.
17 Table 2 summarizes the list of the items evaluated in our cohort and their prerecommended LR for each corresponding status. As recommended, missing values were awarded a score of 1. Prior probability was based on the recommended age-related criterion; this was combined with the minimum required LR for prodromal PD to calculate postprobability of disease using the 80% threshold as a marker for prodromal likelihood. 1 This procedure was reperformed with updated information on age and prodromal features at each follow-up point. Note that all of the participants in our study were first-degree relatives of patients with PD, which awards a 2.5-point score (or 7.5 if sibling had PD with age of onset <50) if genotype is not added. Fifty-two percent of our cohort were carriers of the G2019S-LRRK2 mutation, which awarded a 25-point LR score already at the time of recruitment. For individuals under the age of 50, we used past probability of 0.2% and an LR threshold of 1,200 based on sensitivity assessment.
Statistical Analysis
Mean (standard deviation; SD) and frequency percentages were used to describe numeric and categorical variables, respectively. Univariate comparisons between the LRs of healthy carriers (HC) and healthy noncarriers (HNC) of the G2019S-LRRK2 mutation were performed using independent-samples t tests, Pearson chi-square, or Fisher's exact test, where appropriate.
Linear mixed-model analysis was used to evaluate change in LR over time with random intercepts allowed in order to improve model estimations. Change between assessment points was calculated. Individuals were then stratified into either incident PD or nonconverters (PD-free) according to the presence of PD clinical diagnosis at last follow-up. Differences between groups (i.e., incident PD vs. PD-free) in categorical variables at baseline were tested using Fisher's exact test and the Mann-Whitney U test, respectively. Sensitivity, specificity, PPV, negative predictive value (NPV), and relative risk probability for the diagnosis of incident PD were calculated. We used SPSS for Windows (version 22.0; SPSS, Inc., Chicago, IL) for all statistical analyses. The level of significance was set to P < 0.05.
Results
Participant characteristics are detailed in Table 1 . Subjects were similar between sites in terms of age and sex, and average UPDRS-III was 1.82 6 1.94. Participants in Tel Aviv had lower UPSIT scores than the two groups from the United States (P 5 0.001) whereas participants at CU had higher Montreal Cognitive Assessment (MoCA) scores (P < 0.001) and participants at BI were more likely to report RBD than the 2 other sites (P 5 0.009).
Comparison between HC and HNC at baseline revealed that HC had a higher frequency of constipation (P 5 0.041) and a trend for depression (P 5 0.071), but less frequent reports of RBD (P 5 0.07). As expected based on presence of mutation, HC had higher LR (P 5 0.001) and post-probability scores (P < 0.001) compared to HNC (Table 2) . When removing LRRK2 mutation status from the LR calculation, post-probability was slightly higher in HC than HNC (11.77 6 25.9 vs. 8.65 6 29.65) whereas LR scores showed high variability (37.26 6 113.44 vs. 24.76 6 73.48, respectively), with no between-group differences (P > 0.101).
M I R E L M A N E T A L
A total of 20 participants met criteria for probable prodromal PD (>80% of threshold) at baseline (prevalence, 8.6%; 95% CI: 6.1-13.9), 3 (15%) were parents of patients with PD, 12 (60%) were siblings, and 5 (25%) were children of patients with PD. Seventeen (85%) of these participants were mutation carriers (Fig. 1) . Participants who reached the threshold for probable prodromal PD were older (mean age: 70.05 6 12.46 vs. 48.36 6 12.94; P < 0.0001) and had higher scores on the UPDRS-III (5.25 6 1.37 vs. 1.49 6 1.66; P < 0.001) and lower cognitive scores (mean MoCA: 24.90 6 3.21 vs. 26.77 6 2.40; P 5 0.001), compared to those below the threshold. In addition, a higher frequency of constipation (95% vs. 25.4%; P < 0.0001), somnolence (15.0% vs. 3.3%; P 5 0.014), erectile dysfunction (69.2% vs. 19.4%; P < 0.0001), and hyposmia (50.0% vs. 20.9%; P 5 0.001) was reported by prodromal participants than PD-free. Mean number of prodromal markers was greater for HNC who reached the threshold but remained PDfree than PD-free HC (5.3 vs. 4; Supplementary Fig.  1 ). Thirty participants reached scores above 50% of post-probability prodromal PD. Within this group, 8 were HNC and 22 were HC (Supplementary Fig. 2) .
LR scores tended to slightly increase with follow-up with an average increase of 129% 6 380% in both HC and HNC for the total follow-up period (mean follow-up duration HC group: 47.7 6 13. 2months; HNC, 50.1 611.3 months), with no difference in change over time between groups (P 5 0.63). 
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Contrarily, a significant increase in LR scores was observed in the 20 probable prodromal subjects from baseline to last follow-up (P < 0.0001). This change was significantly greater than that of all PD-free subjects even when genetic status was not included, reflecting a higher frequency of nonmotor symptoms (P < 0.0001; Fig. 2 ). Of the 231 participants, 10 were diagnosed with incident PD during follow-up (4 after 3 years and 6 after 5 years). Six were children and 4 were siblings of PD patients. None of the phenoconvertors were related to one another and all 10 phenoconvertors were carriers of the G2019S-LRRK2 mutation, thus they had significantly higher LRs and post-test probabilities even at baseline assessment. Eight of these 10 subjects reached the 80% threshold for prodromal PD already at baseline assessment, resulting in specificity of 91.82% (95% CI: 86.69-96.94), sensitivity of 80% (95% CI: 55.21- Table 3 ).
Most of the single markers were more frequent in incident PD cases compared with those who remained disease free, with the following reaching statistical significance: UPDRS-III scores (P < 0.001); somnolence (P 5 0.001); constipation (P < 0.0001); and erectile dysfunction (P 5 0.003). The two phenoconverters who did not reach the 80% threshold at baseline assessment scored postprobabilities of 67% and 52.8%. These subjects were 45 and 30 years of age at baseline assessment and developed PD within 38 months. Expanding the threshold to 50% slightly decreased specificity whereas sensitivity increased to 100%. When exploring the classification function without the genetic status, sensitivity markedly declined (Table 3 ; Supplementary Fig. 2 ).
Discussion
The present study is the first to evaluate the MDS Research Criteria for Prodromal PD in carriers of the G2019S-LRRK2 mutation and the first among Ashkenazi Jews. Our study investigated the utility and validity of using the MDS Research Criteria in this at-risk population and the sensitivity of the criteria in identifying prodromal PD in this unique cohort.
As expected, HC had higher LR and post-probability scores compared to HNC. This is not surprising given that the presence of the G2019S-LRRK2 mutation, even without additional symptoms, increases the LR. Mathematically, carriers can meet the threshold for prodromal PD with just three to four additional prodromal markers. By contrast, HNC need to have a larger number of prodromal markers to reach the 80% post-probability threshold (recall Supplumentary Fig.  1 ). In accord with earlier reports, 19 HC demonstrated slightly more nonmotor symptoms, such as constipation and depression, compared to HNC. Previous studies reported less hyposmia and RBD in patients with AJ and non AJ LRRK2-PD, as compared to idiopathic PD cases.
18
, [20] [21] [22] Consistent with these findings, olfaction did not differ between HC and HNC whereas there was a trend for less RBD in HC than HNC.
Change in post-probability scores between PD-free HC and HNC over the 5-year follow-up period was similar. The assumption underlying the MDS Research Criteria for Prodromal PD is that time-dependent prodromal markers should have a steeper increase in prodromal subjects as opposed to low-risk groups. Indeed, rate of change in the prodromal subjects was significantly faster than in the PD-free subjects. This difference between groups was already observed at the initial follow-up assessment (19 months post-baseline), suggesting that exploring change in individuals with minimal symptoms, even after short periods of time, can help increase the likelihood of identifying potential phenoconversion.
These findings attest to the stability of the criteria, but highlight the limitations of some of the timedependent clinical markers used for the criteria. Many of these markers are measured using self-report questionnaires (i.e., RBDQ, SCOPA-AUT, NMSQ, and ESS), which may impact the validity and accuracy of the information as compared to quantitative measures (i.e., polysomnography [PSG] ). In our study, motor function was assessed using the UPDRS-III, which lacks sensitivity for mild motor changes. The MDS Research Criteria for Prodromal PD defined LR for quantitative motor tests of the upper extremity, but not lower extremity function or gait. 1 Previous studies have shown subtle motor changes in LRRK2 carriers and individuals with SN hyperechochogenicity using instrumented gait and motor function assesssment. [23] [24] [25] [26] [27] Adding such objective quantitative measures may enhance the sensitivity of the criteria for change overtime.
We found a prevalence of probable prodromal PD 1 in 8.6% of our cohort. This prevalence is much higher than the 2.2% reported in the general older population 4 and 0.77% in the TREND study, 3 but significantly lower than the 60.3% reported in confirmed RBD cases.
2 Specificity predicting incident PD in our % and 95% CI are presented.
carrier group was high at 91.8% and NPV of 98% whereas sensitivity was slightly lower at 80%, similar to that of RBD cases, 2 demonstrating the value of this approach. When we expanded the threshold for possible prodromal (>50% probability), we found a prevalence of 12.9% in the cohort, with 22 subjects in the HC group (18.3%) and 8 of the HNCs (7.2%) reaching the threshold. This approach slightly decreased specificity (88.18%), but increased sensitivity to 100%. The MDS Research Criteria for Prodromal PD set an 80% threshold for post-probability in order to enhance specificity to define target populations for future disease-prevention trials. However, similar to the findings reported by Mahlknecht and colleagues, 4 using a post-probability threshold of 50% significantly enhanced sensitivity while the decrease in specificity was minute. Applying a broader definition may assist in recruitment and account for variability in clinical trials. Interestingly, when we calculated classification functions without accounting for genetic status, sensitivity significantly declined by approximately 50%. Considering the low penetrance of the G2019S-LRRK2, the NPV may be highly valuable in future disease prevention clinical trials given that it may be useful in identifying, with high probability, those individuals who are unlikely to manifest.
Two of the incident PD subjects were not identified as prodromal PD at the time of initial assessment. Both individuals were younger than 50 years of age, which was the minimum past-probability set by the MDS Task Force. This is an important observation given that approximately 10% of all patients with PD are diagnosed before the age of 50. 28 Thus, it seems likely that prodromal symptoms could be detected at a much younger age and perhaps the criteria should be expanded. On the other hand, higher post-probability scores were observed in older individuals above 80 years of age. It is important to consider that a score of 4 points on the UPDRS-III increases the LR 10-fold. Many older adults are likely to present motor impairments that can result in a higher UPDRS-III score, whereas the frequency of nonmotor symptoms increases with age. Interestingly, the median LR scores of our older group (>80 years of age) was higher than the threshold for probable PD defined by the MDS Research Criteria for Prodromal PD (recall Fig. 1 ). This may likely have an effect on the specificity of the criteria. The Bruneck study, 4 evaluated the criteria in older adults. However, the age range of the participants in that study was between 61.4 and 78.8 years. Thus further investigation of the criteria in older and younger adults is needed to fully assess the advantages and limitations of the criteria in these populations 29 and their applicability to broad clinical cohorts.
The research approach to develop this prodromal probability for the general population is certainly comprehensive, but may need to be modified for use in specific genetic groups. For example, previous studies have shown a similar gender ratio in G2019S-LRRK2 PD. 30 The risk scores provided in the criteria award higher risk to males than females based on the ratio observed in incident IPD. This should probably be modified to improve sensitivity. Furthermore, current estimations regarding G2019S penetrance in AJ is 26% at age 80. 7 Presently, penetrance estimations are not incorporated into the Research Criteria for Prodromal PD meaning, the existence of genetic mutation awards a flat LR score regardless of age. This method assumes a liner relationship whereas risk distribution of carrying the mutation varies based on age. It would be of interest to include estimations of penetrance and distribution given that it may improve the accuracy, sensitivity, and specificity of the criteria and is highly important to enable the estimation of time to phenoconversion and identifying potential participants for future disease modifying clinical trials. Nevertheless, the sensitivity observed in our cohort without including the genetic status was still higher (40%) than that observed in other risk cohorts, 3 reaffirming the suitability of the criterion for such genetic cohorts.
Limitations and Strengths
This study was conducted in AJ carriers and noncarriers of the G2019S-LRRK2 mutation. All of our subjects were first-degree relatives of PD patients, thus sensitivity and specificity estimates would be different if these conditions do not apply. Nevertheless, using such a population allowed us to investigate diagnostic accuracy with higher statistical power. Our study lacked data on some high-LR markers, namely dopaminergic PET/SPECT and PSG. Including such data would likely improve estimation even further. Last, the time to develop PD is still unclear and may rely on many aspects, including, for example, reserve capacity. Twelve of our prodromal subjects remained PD-free at 5 years' follow-up. It is likely that, with a longer follow-up, additional prodromal subjects would have developed the disease.
